ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
•18 May 2025 14:38

Weekly Deals Digest (18 May) - CATL, Hengrui, ESR, OneConnect, Mayne, Nissin, Nippon Road, TechnoPro

A weekly summary of key developments across ECM and Event-Driven names tracked by us across Hong Kong, Australia, NZ, Singapore, Japan, Indonesia,...

Logo
587 Views
Share
bullish•Pop Mart
•16 May 2025 06:57

FXI Rebalance Preview: Pop Mart (9992 HK) Pops Up Again

Pop Mart could replace China Railway in the FXI ETF. Pop Mart is also a potential inclusion to other indices. Shorts have been increasing in both...

Logo
782 Views
Share
•15 May 2025 15:16

Jiangsu Hengrui Pharma H Share Listing (1276 HK): Valuation Insights

The proposed AH discount can be argued as either light or attractive. I lean toward the latter and would participate in the H Share listing.

Logo
559 Views
Share
•15 May 2025 12:17

Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value

Jiangsu Hengrui Medicine (600276 CH), a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing. In this note, we...

Logo
754 Views
Share
x